Good news keeps pouring in: Jiuzhou Pharmaceutical’s Kangchuanji Pharmaceutical has helped its partner obtain marketing approval for Rosuvastatin–Ezetimibe Tablets (I).
2026-07-03
Keywords：
Related information
From January to July 2026, Nanjing Kangchuanji Pharmaceutical Technology Co., Ltd., leveraging its deep-rooted pharmaceutical R&D expertise and mature end-to-end CDMO capabilities, has provided robust support for the innovative R&D and commercialization of its partner companies, achieving further regulatory‑review milestones in collaboration with multiple partners. According to the NMPA’s public announcement of drug approval documents, a total of 12 drug products (covering 15 specifications) have been successfully approved or passed consistency evaluation, demonstrating significant results in translating innovative research into tangible outcomes.
2026-08-04
On August 17, the CDE released a draft of the “Technical Guidance for the Application of Physiologically Based Pharmacokinetic Models in Pediatric Drug Development” for public comment.
2024-10-27
Good news keeps pouring in: Jiuzhou Pharmaceutical’s Kangchuanji Pharmaceutical has helped its partner obtain marketing approval for Rosuvastatin–Ezetimibe Tablets (I).
2026-07-03
Please contact us for more detailed information.
Kangchuanji Pharmatech looks forward to working with you and jointly creating a bright future!
Follow us
Nanjing Kangchuanji Pharmatech Co., Ltd.
Contact Us：18020149597（HR）
Recruitment Email:recruit@kcjpharma.com
Address: 2nd Floor, Building 5, No.199 Wenfang Road, Jiangning District, Nanjing, Jiangsu Province, China（Jiangning High-tech Park）
Copyright © Nanjing Kangchuanji Pharmatech Co., Ltd.